01827 MIRICOR
- 1.270
- 0.0000.00%
MIRICOR News
The market is picking up, and listed companies are pouring in medical and aesthetic institutions. Who will win the next “C-rank material”?
Catalyzed by various factors, the medical and aesthetic market recovered to a certain extent in the first quarter, while the performance of listed companies, whether midstream medical and aesthetic institutions or upstream producers, has steadily improved since this year.
Express News | General Administration of Market Regulation: Maintain a high-pressure crackdown on illegal acts of medical and aesthetic advertising and strictly regulate the publication of medical and aesthetic advertisements
Express News | Fangzheng Securities: The cosmetics, medical and aesthetic industries are expected to usher in strong breakthroughs
The Little Peak of Medicine and Aesthetics is here! There was a wave of beauty concentrated before the Spring Festival, but why did the practitioners continue to complain? |Industry Watch
Ultrasound cannons are booked three days in advance, and the administration is transferred to the front desk to receive customers... A Financial Association reporter recently visited several medical and aesthetic institutions in Chengdu and found that as the Spring Festival approaches, there has been a marked increase in the number of consumers visiting hospitals for consultation and treatment, and some popular programs require advance reservations.
Medical and aesthetic recovery stalled in the second half of the year, triggering a price war. Listed companies target a new “optoelectronic anti-aging” track|year-end inventory
Financial Services Association, December 26 (Reporter He Fan) As the end of the year progresses, the medical and aesthetic market does not seem to be “in full swing” as predicted at the beginning of the year.
MIRICOR: Interim Report 2023/2024
Miricor Swings to Loss in Fiscal H1
Miricor Enterprises Holdings (HKG:1827) swung to a loss of HK$13.1 million, or HK$0.0326 per share, in the first fiscal half, from a profit of HK$3.4 million, or HK$0.0085 per share, in the year-ago p
Zhuojia Holdings (01827.HK)'s interim earnings of approximately HK$237 million increased by about 11.8% year over year
Gelonghui November 24丨Zhuojia Holdings (01827.HK) announced that for the six months ended September 30, 2023, the company's revenue was approximately HK$237 million, an increase of about 11.8% over the previous year. Losses attributable to company owners during the period were approximately HK$13.1 million (for the six months ended 30 September 2022: profit of approximately HK$3.4 million).
MIRICOR: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
Miricor Enterprises to Incur Loss in Fiscal H1
Miricor Enterprises Holdings (HKG:1827) warned it will incur a net loss of not more than HK$14 million in the fiscal first half, compared to a net profit of approximately HK$3.4 million a year earlier
Zhuojia Holdings (01827) issued a profit warning. It expects a net loss of no more than HK$14 million in the medium term to a year-on-year profit to loss
Zhuojia Holdings (01827) announced that the Group expects to make a net loss for the 6 months ending September 30, 2023...
Zhuojia Holdings (01827.HK) plans to hold a board meeting on November 24 to approve the interim results
Gelonghui November 14|Zhuojia Holdings (01827.HK) announced that the company will hold a board meeting on November 24, 2023 (Friday) to (including) approve the interim results of the company and its subsidiaries for the six months ended September 30, 2023 and their publication, and consider the proposed payment of interim dividends (if any).
MIRICOR: ANNUAL REPORT 2022/23
Miricor Swings to Loss in FY23
Miricor Enterprises Holdings (HKG:1827) swung to a loss of HK$20.5 million, or HK$0.0513 per share, in the fiscal year ended March 31, from a profit of HK$25.4 million, or HK$0.0635 per share, a year
Featured Announcements | Taobo: The total sales volume of the retail and wholesale business in the past fiscal quarter recorded a low 20-30% year-on-year increase
Shiyao Group: The first domestic anti-GFRAL monoclonal antibody JMT203 was approved for clinical trials in China; L'Occitane: Group sales reached 2,135 billion euros in FY2023.
MIRICOR: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 MARCH 2023
Zhuojia Holdings (01827.HK) will hold a board meeting on June 26 to approve annual results
Gelonghui, June 13, 丨 Zhuojia Holdings (01827.HK) announced that the company will hold a board meeting on June 26, 2023 to (including) approve the audited annual results and publication of the company and its subsidiaries for the year ending March 31, 2023, and consider recommending the payment of a final dividend (if any).
MIRICOR: DATE OF BOARD MEETING
Express News | Eleven departments jointly issued the “Guiding Opinions on Further Strengthening the Supervision of the Medical Aesthetic Industry”
Express News | National Health Commission: Further strengthen spot checks on medical institutions that provide medical, aesthetic, assisted reproductive, etc.
Analysis
Price Target
No Data
